Evidence map›Paper›PMID 39158065›Full record

ArticleBlood advances2024

Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity.

Brian C Shaffer, Samantha Brown, Stephanie Chinapen, Kathryn E Mangold, Oscar Lahoud, Francisco Lopez-Jimenez, Wendy Schaffer, Jennifer Liu, Sergio Giralt, Sean Devlin and 11 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Brian C ShafferDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Samantha BrownDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5352-974X
Stephanie ChinapenDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6308-9346
Kathryn E MangoldDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Oscar LahoudDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3291-286X
Francisco Lopez-JimenezDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Wendy SchafferDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Jennifer LiuDepartment of Medicine, Weill Cornell Medical College, New York, NY.
Sergio GiraltDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-1944-5053
Sean DevlinDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Gunjan ShahDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael ScordoDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Esperanza PapadopoulosDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6066-1861
Heather LandauDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3152-1189
Saad UsmaniDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Miguel-Angel PeralesDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-5910-4571
Paul A FriedmanDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5052-2948
Bernard J GershDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Itzhak Zachi AttiaDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.ORCID 0000-0002-9706-7900
Peter A NoseworthyDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Ioanna KosmidouDepartment of Medicine, Weill Cornell Medical College, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1985 to 2023
$59.0M
Targeting Drug-Resistant Castration Resistant Prostate Cancer via LIMK2R01CA237660 · NCI · PURDUE UNIVERSITY · PI RATLIFF, TIMOTHY L. · 2020 to 2024
$1.2M
NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA237660
6 · The paper itself

Abstract

abstractArtificial intelligence (AI)-enabled interpretation of electrocardiogram (ECG) images (AI-ECGs) can identify patterns predictive of future adverse cardiac events. We hypothesized that such an approach would provide prognostic information for the risk of cardiac complications and mortality in patients undergoing hematopoietic cell transplantation (HCT). We retrospectively subjected ECGs obtained before HCT to an externally trained, deep-learning model designed to predict the risk of atrial fibrillation (AF). Included were 1377 patients (849 autologous [auto] HCT and 528 allogeneic [allo] HCT recipients). The median follow-up was 2.9 years. The 3-year cumulative incidence of AF was 9% (95% confidence interval [CI], 7-12) in patients who underwent auto HCT and 13% (10%-16%) in patients who underwent allo HCT. In the entire cohort, pre-HCT AI-ECG estimate of AF risk correlated highly with the development of clinical AF (hazard ratio [HR], 7.37; 95% CI, 3.53-15.4; P < .001), inferior survival (HR, 2.4; 95% CI, 1.3-4.5; P = .004), and greater risk of nonrelapse mortality (NRM; HR, 95% CI, 3.36; 1.39-8.13; P = .007), without increased risk of relapse. Association with mortality was only noted in allo HCT recipients, where the risk of NRM was greater. The use of cyclophosphamide after transplantation resulted in greater 90-day incidence of AF (13% vs 5%; P = .01) compared to calcineurin inhibitor-based graft-versus-host disease prophylaxis, corresponding to temporal changes in AI-ECG AF prediction after HCT. In summary, AI-ECG can inform risk of posttransplant cardiac outcomes and survival in HCT patients and represents a novel strategy for personalized risk assessment.

Indexed as

Artificial IntelligenceElectrocardiographyHematopoietic Stem Cell TransplantationAdultAgedAtrial FibrillationFemaleHumansMaleMiddle AgedPrognosisRetrospective Studies

Identifiers

PMID39158065
PMCPMC11550362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.